Akèy › Kansè Poumon ki pa ti selil › Arizona › Tucson
Etid klinik pou Kansè Poumon ki pa ti selil nan Tucson, AZ
17 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Tucson (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Ap rekriteFaz 3
- The University of Arizona Cancer Center - North Campus ( Site 0163), Tucson
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #1, Tucson
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- The University of Arizona Cancer Center - North Campus, Tucson
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Ap rekriteFaz 3
- Research Site, Tucson
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Ap rekriteFaz 3
- Southern Arizona VA Health Care System, Tucson
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Ap rekriteFaz 1/2
- Arizona Cancer Center at UMC North/University Medical Center, Tucson
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Research Site, Tucson
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Ap rekriteFaz 2/3
- Arizona Clinical Research Center, Tucson
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- The University of Arizona Cancer Center - North Campus, Tucson
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- USOR Arizona Oncology Associates, Tucson
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Ap rekriteFaz 1/2
- University of Arizona Cancer Center, Tucson
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Ap rekriteFaz 1
- University of Arizona, Tucson
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Ap rekriteFaz 1
- University of Arizona Cancer Center - Tucson /ID# 262698, Tucson
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Banner University Medical Center - Tucson, Tucson
- University of Arizona Cancer Center-North Campus, Tucson
The Impact of Exercise on the Tumor Microenvironment in Patients With Lung Cancer
Ap rekriteVolontè an sante akeyi
- University of Arizona Cancer Center, Tucson
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 111, Tucson
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
Ap rekriteFaz 1
- The University of Arizona Cancer Center, Tucson
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY121 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH57 etid
- Washington, DC55 etid
Lòt etid nan Tucson
- Kansè nan tete20 etid
- Obèsite18 etid
- Sipwa15 etid
- Kansè Metastatik14 etid
- Kansè (tout kalite)12 etid
- Maladi kadyovaskilè12 etid
- Kansè kolorektal11 etid
- Kansè pwostat11 etid
- Dyabèt Tip 211 etid
- Maladi fwa steatotik10 etid
- Ensifizyans kadyak10 etid
- Hypertension artérielle10 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.